New Study Supports Favorable Sexual Function Profile for Nymox's NX-1207 for Prostate Enlargement
April 16 2013 - 10:32AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today
positive new study findings which have demonstrated that the
Company's NX-1207 Phase 3 treatment for benign prostatic
hyperplasia (BPH or prostatic enlargement) has no detectable effect
on key male structures involved in sexual function. This study has
provided new data which offers further scientific support of highly
selective sparing of prostatic nerves after NX-1207 treatment. In
addition, over 1000 patients in clinical trials who have received
Nymox's NX-1207 have not shown any clinical sexual problems related
to the drug. One of the several major problems with other existing
prostate treatments is the predictable collateral damage to sexual
organs which produces serious problems such as impotence, loss of
libido, and retrograde ejaculation.
In other studies, intraprostatic NX-1207 has been shown to have
no effects on adjacent key organs such as penis and testis, seminal
vesicles, urethra and bladder. Male hormone levels are unaffected
by NX-1207 treatment.
Surgical and other minimally invasive treatments for benign
prostatic hyperplasia (BPH) are non-selective in their effects on
the prostate. The end result is improved urinary function at the
undesirable cost of lost sexual function. These treatments are
known to cause long-term impairment or loss of sexual function in a
significant percentage of treated patients.
Drugs that provide only minor improvement in urination
frequently produce sexual problems. For example, 5-α-reductase
inhibitors (5ARI) often lead to loss of libido, impotence, or male
breast enlargement (gynecomastia). Alpha-blocker drugs frequently
cause retrograde ejaculation (ejaculation into the bladder) or
impotence.
Full results on the new study will be presented at upcoming
medical meetings and in publications.
NX-1207 is a novel patented drug developed by Nymox which is
currently in Phase 3 trials for BPH and Phase 2 for localized
prostate cancer. The drug has successfully completed a series of
blinded controlled multi-center U.S. clinical trials where a single
dose of NX-1207 has been found to produce on average symptomatic
improvements about double that reported for currently approved BPH
drugs without causing the sexual or cardiovascular side effects
associated with those drugs. Follow-up studies have shown evidence
of long lasting benefit with a significant proportion of men who
received a single dose reporting maintained improvement in BPH
symptoms without other treatments for up to 7½ years.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Brian Doyle
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024